Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 2005-2010

  Shimura, T ^a,b   Fuse, N ^a   Yoshino, T ^a   Minashi, K ^a   Tahara, M ^a   Doi, T ^a   Joh, T ^b   Ohtsu, A ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; FOLFIRI; FOLFOX; Interstitial lung disease; Pulmonary toxicity

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; STEROID; TEGAFUR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER METASTASIS; LIVER RESECTION; LUNG DISEASE; LUNG FIBROSIS; LUNG INFILTRATE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RECTUM CANCER; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957147133     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq061     Document Type: Article

References (31)

1. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
2. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
3. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
4. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
5. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
9. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133: 528-538.
10. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33: 98-105.
11. Ohori H, Takahashi M, Ogasawara N et al. [Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)]. Gan To Kagaku Ryoho 2009; 36: 295-298.
12. Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008; 102: 273-279.
13. Arevalo Lobera S, Sagastibeltza Marinelarena N, Elejoste Echeberria I et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008; 10: 764-767.
14. Garrido M, O'Brien A, Gonzalez S et al. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 2007; 132: 1997-1999.
15. Pasetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol 2006; 12: 5907-5908.
16. Gagnadoux F, Roiron C, Carrie E et al. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002; 25: 388-390.
17. Maindrault-Goebel F, Louvet C, Andre T et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-1342.
18. Andre T, Louvet C, Maindrault-Goebel F et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347.
19. Brinkman GL, Coates EO Jr. The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis 1963; 87: 684-693.
20. Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8: 303-306.
21. Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45: 93-104.
22. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 2549-2556.
23. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-1229.
24. Fukuoka M, Niitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
25. Pitot HC, Wender DB, O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-2919.
26. Yague XH, Soy E, Merino BQ et al. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 2005; 7: 515-517.
27. Trisolini R, Lazzari Agli L, Tassinari D et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 2001; 18: 243-245.
28. Jung KH, Kil SY, Choi IK et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis 2006; 10: 1181-1182.
29. Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000; 11: 709-713.
30. U.S. Food and Drug Administration. Drug Approval Package: eloxatin (oxaliplatin) NDA #021492. In Edition 2004; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021492_s002_EloxatinTOC.cfm. (last accessed 29 December 2009).
31. U.S. Food and Drug Administration. Drug Approval Package: eloxatin (oxaliplatin) NDA #21-492. In Edition 2002; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-492_Eloxatin.cfm. (last accessed 29 December 2009).